Equillium, Inc. (EQ) - Q1 2026 10-Q Summary
Business Context and Reporting Period
Equillium, Inc. is a biotechnology innovator developing novel therapies for severe autoimmune and inflammatory disorders. The company operates as a single segment focused on advancing its primary product candidate, EQ504 (a novel aryl hydrocarbon receptor modulator), and evaluating EQ302 (a bi-specific inhibitor of IL-15 and IL-21). This report covers the quarterly period ended March 31, 2026.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5,311) | $(8,654) |
| Net Loss Per Share (Basic & Diluted) | $(0.06) | $(0.24) |
| Operating Expenses | $5,610 | $8,870 |
| Cash and Cash Equivalents (End of Period) | $61,322 | $14,502 |
| Accumulated Deficit | $(221,516) | $(202,461) |
| Net Cash Used in Operating Activities | $(4,301) | $(8,169) |
| Net Cash Provided by Financing Activities | $35,346 | $91 |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately $3.3 million (37%) compared to Q1 2025. Research and Development (R&D) expenses dropped significantly from $5.9 million to $3.0 million, primarily due to the wind-down of clinical studies for Itolizumab (EQ001) and reduced headcount.
- Capital Raise: The company completed a private placement in March 2026, raising gross proceeds of approximately $35.0 million. This resulted in a substantial increase in cash balances from $30.3 million at year-end 2025 to $61.3 million at March 31, 2026.
- Share Count: Weighted-average shares outstanding increased significantly to 96.3 million in Q1 2026 from 35.6 million in Q1 2025, driven by the issuance of common stock and pre-funded warrants in recent private placements.
- Interest Income: Interest income increased to $309,000 from $173,000 due to higher average cash balances.
Guidance, Outlook, and Risks
- Outlook: Management expects to commence a Phase 1 proof-of-mechanism study for EQ504 in mid-2026, with data expected approximately six months thereafter. The company anticipates funding operations into 2029 based on current cash levels.
- Liquidity: As of March 31, 2026, the company had $61.3 million in cash. Management believes this is sufficient to fund operations for at least the next 12 months.
- Future Financing: The company expects to incur additional losses and will need to raise additional capital to complete the development of EQ504 and EQ302. It maintains an At-The-Market (ATM) facility with up to $75.0 million available.
- Risks:
- Cryptocurrency Strategy: The company announced a treasury strategy to potentially invest in digital currencies, introducing volatility risks to financial results.
- Regulatory & Development: Success depends entirely on the clinical development of EQ504 and EQ302; no product revenue is expected in the near term.
- Delisting Risk: The company previously faced Nasdaq minimum bid price compliance issues but regained compliance in August 2025. Continued compliance is not guaranteed.
Investor Verification Checklist
- Verify the timeline and budget for the upcoming Phase 1 study of EQ504 scheduled for mid-2026.
- Confirm the terms and exercise status of the pre-funded warrants issued in the March 2026 and August 2025 private placements (totaling over 48 million shares).
- Assess the potential impact of the announced cryptocurrency treasury strategy on future balance sheet volatility.
- Monitor the company's ability to maintain Nasdaq listing requirements, specifically the minimum bid price.
- Review the status of the potential second closing under the August 2025 Purchase Agreement, which is contingent on clinical milestones and stock price thresholds.